MGC030
/ MacroGenics
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 14, 2025
Key Strategic Priorities for 2025 and 2026
(Macrogenics Press Release)
- "Determine development path for lorigerlimab based on data from the ongoing LORIKEET and LINNET studies. Advance MGC026 and MGC028 programs to assess clinical proof-of-concept. Submit Investigational New Drug (IND) application for MGC030. Initiate IND-enabling studies for two new product candidates. Forge partnerships and collaborations to accelerate development of the Company’s proprietary product candidates and technology platforms."
IND • M&A • Preclinical • Oncology
May 13, 2025
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
(Macrogenics Press Release)
- "First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers; Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC, expected in second half of 2025...MGC026 is currently being evaluated in a Phase 1 dose escalation study in patients with advanced solid tumors, with dose expansion in selected indications expected to initiate in 2025; An Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MGC030 is planned for 2026."
IND • P2 data • Trial status • Castration-Resistant Prostate Cancer • Ovarian Cancer
March 20, 2025
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
(GlobeNewswire)
- "Emerging ADC Pipeline:...(i) MGC026:...MGC026 is currently being evaluated in a Phase 1 dose escalation study in patients with advanced solid tumors, with dose expansion in selected indications expected to initiate in 2025; (ii) MGC028:...The first patient was recently dosed in a Phase 1 study of MGC028 in patients with advanced solid tumors; (iii) MGC030:...An Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for MGC030 is planned for 2026."
IND • Trial status • Solid Tumor
1 to 3
Of
3
Go to page
1